home / openregs

documents

Regulatory documents from Regulations.gov including rules, proposed rules, notices, and supporting materials.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

59 rows where docket_id = "FDA-2015-D-1211" and posted_year = 2023 sorted by posted_date descending

✎ View and edit SQL

This data as json, CSV (advanced)

Suggested facets: subtype, posted_date, posted_month, comment_start_date, open_for_comment, posted_date (date), comment_start_date (date), comment_end_date (date), last_modified (date)

document_type 3

  • Supporting & Related Material 54
  • Notice 3
  • Other 2

posted_year 1

  • 2023 · 59 ✖

agency_id 1

  • FDA 59
id agency_id docket_id title document_type subtype posted_date ▲ posted_year posted_month comment_start_date comment_end_date last_modified fr_doc_num open_for_comment withdrawn object_id
FDA-2015-D-1211-0368 FDA None FDA-2015-D-1211 Reference 7 Van de perre p re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry Supporting & Related Material Background Material 2023-05-12T04:00:00Z 2023 5     2023-05-12T20:07:33Z   0 0 09000064859fc420
FDA-2015-D-1211-0397 FDA None FDA-2015-D-1211 Reference 36_FAIR_Conclusions from the For the Assessment of Individualized Risk (FAIR) group re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry Supporting & Related Material Background Material 2023-05-12T04:00:00Z 2023 5     2023-05-12T20:07:55Z   0 0 09000064859fd93c
FDA-2015-D-1211-0402 FDA None FDA-2015-D-1211 Reference 41_Blood safety implications of donors using HIV preexposure prophylaxis re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry Supporting & Related Material Background Material 2023-05-12T04:00:00Z 2023 5     2023-05-12T20:07:59Z   0 0 09000064859fd941
FDA-2015-D-1211-0394 FDA None FDA-2015-D-1211 Reference 33- O Brien - Donor screening question alternatives to men who have sex with men time deferral Potential (1) re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry Supporting & Related Material Background Material 2023-05-12T04:00:00Z 2023 5     2023-05-12T20:07:52Z   0 0 09000064859fd865
FDA-2015-D-1211-0403 FDA None FDA-2015-D-1211 Reference 42_AABB_Updated Recommendations on Donor Deferral for Use of Antiretroviral Medications for HIV Prevention and Treatment re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry Supporting & Related Material Background Material 2023-05-12T04:00:00Z 2023 5     2023-05-12T20:08:00Z   0 0 09000064859fd942
FDA-2015-D-1211-0362 FDA None FDA-2015-D-1211 Reference 1 REV. Epstein_et_al-2013-Transfusion re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry Supporting & Related Material Background Material 2023-05-12T04:00:00Z 2023 5     2023-05-12T20:07:29Z   0 0 09000064859fbfcf
FDA-2015-D-1211-0370 FDA None FDA-2015-D-1211 Reference 9 HIV and the blood supply re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry Supporting & Related Material Background Material 2023-05-12T04:00:00Z 2023 5     2023-05-12T20:07:35Z   0 0 09000064859fc422
FDA-2015-D-1211-0390 FDA None FDA-2015-D-1211 Reference 29 REV. Custer - Transfusion-transmissible infection re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry Supporting & Related Material Background Material 2023-05-12T04:00:00Z 2023 5     2023-05-12T20:07:50Z   0 0 09000064859fd861
FDA-2015-D-1211-0360 FDA None FDA-2015-D-1211 Recommendations for Evaluating Donor Eligibility Using Individual Risk- Based Questions To Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products; Guidance for Industry; Availability Notice Notice of Availability 2023-05-12T04:00:00Z 2023 5 2023-05-12T04:00:00Z   2023-05-12T12:59:32Z 2023-10252 0 0 09000064859fa444
FDA-2015-D-1211-0387 FDA None FDA-2015-D-1211 Reference 26 Offergeld2014 re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry Supporting & Related Material Background Material 2023-05-12T04:00:00Z 2023 5     2023-05-12T20:07:48Z   0 0 09000064859fd85e
FDA-2015-D-1211-0363 FDA None FDA-2015-D-1211 Reference 2 Stramer_et_al-2013-Transfusion re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry Supporting & Related Material Background Material 2023-05-12T04:00:00Z 2023 5     2023-05-12T20:07:30Z   0 0 09000064859fbfd0
FDA-2015-D-1211-0371 FDA None FDA-2015-D-1211 Reference 10 Current Trends Prevention of Acquired Immune Deficiency Syndrome (AIDS)_ Report of Inter-Agency Recommendations re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry Supporting & Related Material Background Material 2023-05-12T04:00:00Z 2023 5     2023-05-12T20:07:35Z   0 0 09000064859fc423
FDA-2015-D-1211-0374 FDA None FDA-2015-D-1211 Reference 13 Donor-Testing-and-Risk-2012 re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry Supporting & Related Material Background Material 2023-05-12T04:00:00Z 2023 5     2023-05-12T20:07:38Z   0 0 09000064859fd845
FDA-2015-D-1211-0386 FDA None FDA-2015-D-1211 Reference 25 REV. Custer - Blood DROPS re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry Supporting & Related Material Background Material 2023-05-12T04:00:00Z 2023 5     2023-05-12T20:07:47Z   0 0 09000064859fd85b
FDA-2015-D-1211-0399 FDA None FDA-2015-D-1211 Reference 38_NHS Blood and Transplant_Our Improved Donations Safety Check re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry Supporting & Related Material Background Material 2023-05-12T04:00:00Z 2023 5     2023-05-12T20:07:56Z   0 0 09000064859fd93e
FDA-2015-D-1211-0405 FDA None FDA-2015-D-1211 Reference 44_New Ref 44_HIV incidence in US first-time blood donors during 12-month and 3-month MSM deferral policy periods re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry Supporting & Related Material Background Material 2023-05-12T04:00:00Z 2023 5     2023-05-12T20:08:01Z   0 0 09000064859fd944
FDA-2015-D-1211-0385 FDA None FDA-2015-D-1211 Reference 24 REV. Custer2014 re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry Supporting & Related Material Background Material 2023-05-12T04:00:00Z 2023 5     2023-05-12T20:07:46Z   0 0 09000064859fd85a
FDA-2015-D-1211-0395 FDA None FDA-2015-D-1211 Reference 34 Goldman.MSM Policy changes in Canada.Transfusion.2022 re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry Supporting & Related Material Background Material 2023-05-12T04:00:00Z 2023 5     2023-05-12T20:07:53Z   0 0 09000064859fd866
FDA-2015-D-1211-0400 FDA None FDA-2015-D-1211 Reference 39_FDA_Important Information for Potential Donors of Blood and Blood Products re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry Supporting & Related Material Background Material 2023-05-12T04:00:00Z 2023 5     2023-05-12T20:07:56Z   0 0 09000064859fd93f
FDA-2015-D-1211-0404 FDA None FDA-2015-D-1211 Reference 43 New Reference 43_HIV antiretroviral therapy and prevention use in US blood re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry Supporting & Related Material Background Material 2023-05-12T04:00:00Z 2023 5     2023-05-12T20:08:00Z   0 0 09000064859fd943
FDA-2015-D-1211-0379 FDA None FDA-2015-D-1211 Reference 18_FDA Blood Products Advisory Committee Meeting_September 14-15 2000 re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry Supporting & Related Material Background Material 2023-05-12T04:00:00Z 2023 5     2023-05-12T20:07:41Z   0 0 09000064859fd84a
FDA-2015-D-1211-0384 FDA None FDA-2015-D-1211 Reference 23 REV. ACBTSA re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry Supporting & Related Material Background Material 2023-05-12T04:00:00Z 2023 5     2023-05-12T20:07:46Z   0 0 09000064859fd859
FDA-2015-D-1211-0392 FDA None FDA-2015-D-1211 Refernce 31_HIV Risk Behavior Profiles Among Men Who Have Sex with Men Interested in Donating Blood_ADVANCE Study re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry Supporting & Related Material Background Material 2023-05-12T04:00:00Z 2023 5     2023-05-12T20:07:51Z   0 0 09000064859fd863
FDA-2015-D-1211-0401 FDA None FDA-2015-D-1211 Reference 40_Initiation of anti-retroviral therapy during acute HIV-1 infection leads to a high rate of nonreactive HIV serology re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry Supporting & Related Material Background Material 2023-05-12T04:00:00Z 2023 5     2023-05-12T20:07:57Z   0 0 09000064859fd940
FDA-2015-D-1211-0367 FDA None FDA-2015-D-1211 Reference 6 Pubhealthrep00106-0104 re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry Supporting & Related Material Background Material 2023-05-12T04:00:00Z 2023 5     2023-05-12T20:07:33Z   0 0 09000064859fbfd4
FDA-2015-D-1211-0372 FDA None FDA-2015-D-1211 Reference 11 Transfusion-associated_infections re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry Supporting & Related Material Background Material 2023-05-12T04:00:00Z 2023 5     2023-05-12T20:07:36Z   0 0 09000064859fd727
FDA-2015-D-1211-0380 FDA None FDA-2015-D-1211 Reference 19 FDA Workshop on Behavior-Based Donor Deferral in the NAT Era 2006 re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry Supporting & Related Material Background Material 2023-05-12T04:00:00Z 2023 5     2023-05-12T20:07:42Z   0 0 09000064859fd84b
FDA-2015-D-1211-0383 FDA None FDA-2015-D-1211 Reference 22_FDA workshop on Quarantine Release Errors in Blood Establishments_September 2011 re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry Supporting & Related Material Background Material 2023-05-12T04:00:00Z 2023 5     2023-05-12T20:07:45Z   0 0 09000064859fd858
FDA-2015-D-1211-0393 FDA None FDA-2015-D-1211 Reference 32_Caffrey_Removing MSM.Canada.CliniqueTransfusion.2022 re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry Supporting & Related Material Background Material 2023-05-12T04:00:00Z 2023 5     2023-05-12T20:07:52Z   0 0 09000064859fd864
FDA-2015-D-1211-0376 FDA None FDA-2015-D-1211 Reference 15 MMWR_Revised Public Health Service Definition of Persons Who Should Refrain from Donating Blood and Plasma -- United States re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry Supporting & Related Material Background Material 2023-05-12T04:00:00Z 2023 5     2023-05-12T20:07:39Z   0 0 09000064859fd847
FDA-2015-D-1211-0389 FDA None FDA-2015-D-1211 Reference 28 Lucky2014 re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry Supporting & Related Material Background Material 2023-05-12T04:00:00Z 2023 5     2023-05-12T20:07:49Z   0 0 09000064859fd860
FDA-2015-D-1211-0398 FDA None FDA-2015-D-1211 Reference 37_Patel et al_Estimating per-act HIV transmission risk re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry Supporting & Related Material Background Material 2023-05-12T04:00:00Z 2023 5     2023-05-12T20:07:55Z   0 0 09000064859fd93d
FDA-2015-D-1211-0406 FDA None FDA-2015-D-1211 Reference 45_New Ref 45_Modeling the Effect of an Individual-Risk Based Deferral Policy re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry Supporting & Related Material Background Material 2023-05-12T04:00:00Z 2023 5     2023-05-12T20:08:02Z   0 0 09000064859fd945
FDA-2015-D-1211-0364 FDA None FDA-2015-D-1211 Reference 3 Dubin_et_al-2013-Transfusion re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry Supporting & Related Material Background Material 2023-05-12T04:00:00Z 2023 5     2023-05-12T20:07:31Z   0 0 09000064859fbfd1
FDA-2015-D-1211-0365 FDA None FDA-2015-D-1211 Reference 4 Epidemiologic Notes and Reports Pneumocystis carinii Pneumonia among Persons with Hemophilia A re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry Supporting & Related Material Background Material 2023-05-12T04:00:00Z 2023 5     2023-05-12T20:07:31Z   0 0 09000064859fbfd2
FDA-2015-D-1211-0366 FDA None FDA-2015-D-1211 Reference 5 Epidemiologic Notes and Reports Possible Transfusion-Associated Acquired Immune Deficiency Syndrome (AIDS) -- California re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry Supporting & Related Material Background Material 2023-05-12T04:00:00Z 2023 5     2023-05-12T20:07:32Z   0 0 09000064859fbfd3
FDA-2015-D-1211-0375 FDA None FDA-2015-D-1211 Reference 14 Klamroth2014 re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry Supporting & Related Material Background Material 2023-05-12T04:00:00Z 2023 5     2023-05-12T20:07:38Z   0 0 09000064859fd846
FDA-2015-D-1211-0373 FDA None FDA-2015-D-1211 Reference 12 Ward et al_JAMA_256_3_028 re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry Supporting & Related Material Background Material 2023-05-12T04:00:00Z 2023 5     2023-05-12T20:07:37Z   0 0 09000064859fd844
FDA-2015-D-1211-0361 FDA None FDA-2015-D-1211 Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry Other Guidance 2023-05-12T04:00:00Z 2023 5 2023-05-12T04:00:00Z   2024-11-11T21:24:16Z   1 0 09000064859fa827
FDA-2015-D-1211-0369 FDA None FDA-2015-D-1211 Reference 8 FDA Memorandum Recommendations to decrease the Risk of Tramitting AIDS fro Blood donors re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry Supporting & Related Material Background Material 2023-05-12T04:00:00Z 2023 5     2023-05-12T20:07:34Z   0 0 09000064859fc421
FDA-2015-D-1211-0377 FDA None FDA-2015-D-1211 Reference 16_FDA Blood Products Advisory Committee Meeting_December 11 1997 re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry Supporting & Related Material Background Material 2023-05-12T04:00:00Z 2023 5     2023-05-12T20:07:40Z   0 0 09000064859fd848
FDA-2015-D-1211-0396 FDA None FDA-2015-D-1211 Reference 35_Advisory Committee on the Safety of Blood Tissues and Organs (SaBTO)_Donor Selection Criteria Report re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry Supporting & Related Material Background Material 2023-05-12T04:00:00Z 2023 5     2023-05-12T20:07:54Z   0 0 09000064859fd867
FDA-2015-D-1211-0378 FDA None FDA-2015-D-1211 Reference 17_FDA Workshop on Donor Suitability 1998 re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry Supporting & Related Material Background Material 2023-05-12T04:00:00Z 2023 5     2023-05-12T20:07:40Z   0 0 09000064859fd849
FDA-2015-D-1211-0382 FDA None FDA-2015-D-1211 Reference 21 Quarantine-release-errors-white-paper re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry Supporting & Related Material Background Material 2023-05-12T04:00:00Z 2023 5     2023-05-12T20:07:44Z   0 0 09000064859fd84d
FDA-2015-D-1211-0391 FDA None FDA-2015-D-1211 Reference 30_ADVANCE Study re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry Supporting & Related Material Background Material 2023-05-12T04:00:00Z 2023 5     2023-05-12T20:07:50Z   0 0 09000064859fd862
FDA-2015-D-1211-0381 FDA None FDA-2015-D-1211 Reference 20 HHS Advisory Committee for blood safety and availability mtg 2010 re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry Supporting & Related Material Background Material 2023-05-12T04:00:00Z 2023 5     2023-05-12T20:07:43Z   0 0 09000064859fd84c
FDA-2015-D-1211-0388 FDA None FDA-2015-D-1211 Reference 27 Seed2010 re: Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Guidance for Industry Supporting & Related Material Background Material 2023-05-12T04:00:00Z 2023 5     2023-05-12T20:07:48Z   0 0 09000064859fd85f
FDA-2015-D-1211-0274 FDA None FDA-2015-D-1211 Guidance Documents Related to Coronavirus Disease 2019 (COVID–19) Notice General Notice 2023-03-13T04:00:00Z 2023 3 2023-03-13T04:00:00Z   2023-03-13T14:09:01Z 2023-05094 0 0 090000648579b2d7
FDA-2015-D-1211-0151 FDA None FDA-2015-D-1211 Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions To Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products; Draft Guidance for Industry; Availability Notice Notice of Availability 2023-01-30T05:00:00Z 2023 1 2023-01-30T05:00:00Z   2023-02-28T14:29:29Z 2023-01796 0 0 0900006485618fef
FDA-2015-D-1211-0155 FDA None FDA-2015-D-1211 Reference 17_FDA Workshop on Donor Suitability 1998 Supporting & Related Material Background Material 2023-01-30T05:00:00Z 2023 1     2023-01-30T14:18:43Z   0 0 0900006485618a78
FDA-2015-D-1211-0156 FDA None FDA-2015-D-1211 Reference 18_FDA Blood Products Advisory Committee Meeting_September 14-15 2000 Supporting & Related Material Background Material 2023-01-30T05:00:00Z 2023 1     2023-01-30T14:19:40Z   0 0 0900006485618a79
FDA-2015-D-1211-0157 FDA None FDA-2015-D-1211 Reference 19 FDA Workshop on Behavior-Based Donor Deferral in the NAT Era 2006 Supporting & Related Material Background Material 2023-01-30T05:00:00Z 2023 1     2023-01-30T14:20:46Z   0 0 0900006485618a6b
FDA-2015-D-1211-0158 FDA None FDA-2015-D-1211 Reference 22_FDA workshop on Quarantine Release Errors in Blood Establishments_September 2011 Supporting & Related Material Background Material 2023-01-30T05:00:00Z 2023 1     2023-01-30T14:21:52Z   0 0 0900006485618a6c
FDA-2015-D-1211-0152 FDA None FDA-2015-D-1211 Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions To Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products; Draft Guidance for Industry; Availability Other Guidance 2023-01-30T05:00:00Z 2023 1 2023-01-30T05:00:00Z 2023-04-01T03:59:59Z 2025-02-05T02:00:53Z   1 0 0900006485618a68
FDA-2015-D-1211-0159 FDA None FDA-2015-D-1211 New Reference 30_ADVANCE Study Supporting & Related Material Background Material 2023-01-30T05:00:00Z 2023 1     2023-01-30T14:22:43Z   0 0 0900006485618a6d
FDA-2015-D-1211-0160 FDA None FDA-2015-D-1211 New Ref 32- O Brien - Donor screening question alternatives to men who have sex with men time deferral Potential (1) Supporting & Related Material Background Material 2023-01-30T05:00:00Z 2023 1     2023-01-30T14:24:06Z   0 0 0900006485618a6e
FDA-2015-D-1211-0154 FDA None FDA-2015-D-1211 Reference 16_FDA Blood Products Advisory Committee Meeting_December 11 1997 Supporting & Related Material Background Material 2023-01-30T05:00:00Z 2023 1     2023-01-30T14:17:37Z   0 0 0900006485618a77
FDA-2015-D-1211-0153 FDA None FDA-2015-D-1211 New Ref 15 MMWR_Revised Public Health Service Definition of Persons Who Should Refrain from Donating Blood and Plasma -- United States Supporting & Related Material Background Material 2023-01-30T05:00:00Z 2023 1     2023-01-30T14:17:49Z   0 0 0900006485618a6a
FDA-2015-D-1211-0161 FDA None FDA-2015-D-1211 New Ref 37_NHS Blood and Transplant_Our Improved Donations Safety Check Supporting & Related Material Background Material 2023-01-30T05:00:00Z 2023 1     2023-01-30T14:24:58Z   0 0 0900006485618a7c

Advanced export

JSON shape: default, array, newline-delimited, object

CSV options:

CREATE TABLE documents (
    id TEXT PRIMARY KEY,
    agency_id TEXT,
    docket_id TEXT REFERENCES dockets(id),
    title TEXT,
    document_type TEXT,
    subtype TEXT,
    posted_date TEXT,
    posted_year INTEGER,
    posted_month INTEGER,
    comment_start_date TEXT,
    comment_end_date TEXT,
    last_modified TEXT,
    fr_doc_num TEXT,
    open_for_comment INTEGER,
    withdrawn INTEGER,
    object_id TEXT
);
CREATE INDEX idx_docs_agency ON documents(agency_id);
CREATE INDEX idx_docs_docket ON documents(docket_id);
CREATE INDEX idx_docs_date ON documents(posted_date);
CREATE INDEX idx_docs_year ON documents(posted_year);
CREATE INDEX idx_docs_type ON documents(document_type);
CREATE INDEX idx_docs_frnum ON documents(fr_doc_num);
CREATE INDEX idx_docs_comment_end ON documents(comment_end_date) WHERE comment_end_date IS NOT NULL AND withdrawn = 0;
Powered by Datasette · Queries took 3854.813ms · Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API